Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment? Commentary Journal Article

  

Authors:	Janjigian, Y. Y.; Miller, V. A.
Article Title:	Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment? Commentary
Keywords:	immunohistochemistry; protein kinase b; protein phosphorylation; overall survival; exon; gene deletion; clinical trial; cancer recurrence; erlotinib; cancer growth; patient selection; disease free survival; cancer staging; disease association; lung non small cell cancer; epidermal growth factor receptor; smoking; mutational analysis; prediction; protein tyrosine kinase inhibitor; molecular marker; fluorescence in situ hybridization; drug response; gefitinib; short survey; aspiration biopsy; point mutation; drug sensitivity
Journal Title:	Nature Clinical Practice Oncology
Volume:	5
Issue:	1
ISSN:	1743-4254
Publisher:	Nature Publishing Group
Date Published:	2008-10-01
Start Page:	10
End Page:	11
Language:	English
DOI:	10.1038/ncponc0997
PROVIDER:	scopus
PUBMED:	17955045
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-41949123747&partnerID=40&md5=6061f40c4919ce56509c360c671b532e
Notes:	--- - "Export Date: 17 November 2011" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/14629